NCT03970226View on ClinicalTrials.gov

Tocilizumab in Children With ACP

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

May 26, 2024

Study Completion Date

December 31, 2025

Conditions
Adamantinomatous Craniopharyngioma
Interventions
DRUG

Tocilizumab

"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Colorado, Denver

OTHER

NCT03970226 - Tocilizumab in Children With ACP | Biotech Hunter | Biotech Hunter